JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Fermé

SecteurSoins de santé

7.65 -0.78

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.59

Max

7.91

Chiffres clés

By Trading Economics

Revenu

8M

-25M

Marge bénéficiaire

-8,121.359

Employés

202

EBITDA

9.3M

-26M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+71.63% upside

Dividendes

By Dow Jones

Prochains Résultats

12 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

284M

561M

Ouverture précédente

8.43

Clôture précédente

7.65

Sentiment de l'Actualité

By Acuity

18%

82%

29 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Omeros Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 oct. 2025, 15:36 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct. 2025, 13:27 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15 oct. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Comparaison

Variation de prix

Omeros Corp prévision

Objectif de Prix

By TipRanks

71.63% hausse

Prévisions sur 12 Mois

Moyen 13.13 USD  71.63%

Haut 20 USD

Bas 6.269 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

6.265 / 7.49Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

29 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat